Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT

Maria Queralt Salas, MD, Arjun Law, MDDM, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, David Loach, MD, Zeyad Al-Shaibani, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Auro Viswabandya, MDDM

Blood (2019) 134 (Supplement_1): 3344.

https://doi.org/10.1182/blood-2019-128639

Published: 2019

Journal Articles

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Maria Queralt Salas, MD, Shiyi Chen, Wilson Lam, MD, David Loach, MD, Fotios V. Michelis, MD PhD, Zeyad Al-Shaibani, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM, Rajat Kumar, MD, Jonas Mattsson, MD, Arjun Law, MDDM

Blood (2019) 134 (Supplement_1): 4590.

https://doi.org/10.1182/blood-2019-126236

Published: 2019

Journal Articles

Improved Gvhd Free, Relapse Free Survival Using Dual T-Cell Depletion with ATG and Ptcy in Matched Unrelated Donor RIC Allo-HSCT

Maria Queralt Salas, MD, Wilson Lam, MD, Arjun Law, MDDM, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Zeyad Al-Shaibani, David Loach, MD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Auro Viswabandya, MDDM

Blood (2019) 134 (Supplement_1): 4594.

https://doi.org/10.1182/blood-2019-128720

Published: 2019

Journal Articles

Dual T-Cell Depletion with a Very Low Dose of ATG and Ptcy Provides an Effective Control of Acute Gvhd in PBSC RIC Allo-HSCT

Maria Queralt Salas, MD, Arjun Law, MDDM, Wilson Lam, MD, David Loach, MD, Zeyad Al-Shaibani, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Auro Viswabandya, MDDM

Blood (2019) 134 (Supplement_1): 5669.

https://doi.org/10.1182/blood-2019-128532

Published: 2019

Journal Articles

Outcomes of Therapy Related Acute Lymphoblastic Leukemia in Adults after Allogeneic Stem Cell Transplantation - Twenty-Year Experience from a Tertiary Care Center

RAM V Nampoothiri, Arjun Law, MDDM, Wilson Lam, MD, Zeyad Al-Shaibani, David Loach, MD, Carol Chen, Dennis Dong Hwan Kim, MD PhD, Fotios V. Michelis, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM

Blood (2019) 134 (Supplement_1): 5717.

https://doi.org/10.1182/blood-2019-124834

Published: 2019

Journal Articles

Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneichematopoietic Cell Transplantation to Predict Outcomes

Maria Queralt Salas, MD, Eshetu G Atenafu, M.Sc., P.Stat, Ora Bascom, Allo-HSCT Coordinator, Leeann Wilson, RN, BSc, BSc N(HON), CON(c), Arjun Law, MDDM, Wilson Lam, MD, David Loach, MD, Zeyad Al-Shaibani, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM, Jonas Mattsson, MD, Alibhai M.H. Shabbir, MD, Rajat Kumar, MD

Blood (2019) 134 (Supplement_1): 380.

https://doi.org/10.1182/blood-2019-126071

Published: 2019

Journal Articles

Predictors of Outcomes in Adult Patients with Therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Twenty Year Experience from a Tertiary Care Centre

RAM V Nampoothiri, Arjun Law, MD, Wilson Lam, MD, Zeyad Al-Shaibani, David Loach, MD, Carol Chen, Dennis Dong Hwan Kim, MD PhD, Fotios V. Michelis, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MD

Blood (2019) 134 (Supplement_1): 5737.

https://doi.org/10.1182/blood-2019-128445

Published: 2019

Journal Articles

Combination of ATG and Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Peripheral Blood Stem Cell Transplants for High-Risk Hematological Malignancies- a Single Centre Experience

Shruti Prem Sudha, MD DM, Eshetu G Atenafu, M.Sc., P.Stat, Queralt Salas Gay, MD, Zoe Evans, Zeyad Al-Shaibani, MD, David Loach, MD, Arjun Law, MDDM, Wilson Lam, MD, Santhosh Thyagu, MD DM, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Auro Viswabandya, MD DM

Blood (2018) 132 (Supplement 1): 4569.

https://doi.org/10.1182/blood-2018-99-111955

Published: 2018

Journal Articles

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Uday Deotare, MD DM, David Loach, MD, Fotios V. Michelis, MD PhD, Dennis D. Kim, MD PhD, Santhosh Thyagu, MBBS, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Auro Viswabandya, MD DM

Blood (2016) 128 (22): 3430.

https://doi.org/10.1182/blood.V128.22.3430.3430

Published: 2016

Journal Articles

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Uday Deotare, MD DM, David Loach, MD, Fotios V. Michelis, MD PhD, Dennis D. Kim, MD PhD, Santhosh Thyagu, MBBS, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Auro Viswabandya, MD DM

Blood (2016) 128 (22): 5781.

https://doi.org/10.1182/blood.V128.22.5781.5781

Published: 2016

Journal Articles

Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation

Samantha J Mayo, RN, PhD, Hans A. Messner, MD/PhD, Sean B. Rourke, PhD, Doris Howell, RN PhD, J. Charles Victor, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Vikas Gupta, MD MRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, Laura McGillis, BScN, MN, RN(EC), CONc, Jieun Uhm, MD, Fotios V. Michelis, MDPhD, Naheed Alam, MBBS,MD, Anna Lambie, RN NP, Dawn Breen, RN, David Loach, MD, Christine Piescic, RN, Kelly Metcalfe, RN PhD

Blood (2015) 126 (23): 3289.

https://doi.org/10.1182/blood.V126.23.3289.3289

Published: 2015

Journal Articles

Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience

Fotios V. Michelis, MDPhD, Rouslan Kotchetkov, MD, Rebecca M. Grunwald, Aamir Azeem, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Laura McGillis, NP, Anna Lambie, NP, David Loach, MD, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Dennis D. Kim, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 1179.

https://doi.org/10.1182/blood.V124.21.1179.1179

Published: 2014

Journal Articles

Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

Fotios V. Michelis, MDPhD, Rouslan Kotchetkov, MD, Aamir Azeem, Rebecca M. Grunwald, Jieun Uhm, MD, Naheed Alam, MBBS, MD, Anna Lambie, NP, Laura McGillis, NP, David Loach, MD, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Dennis D. Kim, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 1237.

https://doi.org/10.1182/blood.V124.21.1237.1237

Published: 2014

Journal Articles

A Risk Score to Predict CMV Viremia within the First 100 Days after Allogeneic Stem Cell Transplantation Based on Pre-Transplant Parameters

Feras Alfraih, MD, John Kuruvilla, MD, Naheed Alam, MBBS,MD, Anna Lambie, NP, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Jieun Uhm, MD, David Loach, MD, Eshetu G Atenafu, M.Sc., Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 3877.

https://doi.org/10.1182/blood.V124.21.3877.3877

Published: 2014

Journal Articles

Clinical Characteristics, Risk Factors and Outcomes of CMV Disease after Allogeneic Stem Cell Transplantation

Feras Alfraih, MD, Naheed Alam, MBBS,MD, Anna Lambie, NP, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Jieun Uhm, MD, David Loach, MD, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 3879.

https://doi.org/10.1182/blood.V124.21.3879.3879

Published: 2014

Journal Articles

Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Fotios V. Michelis, MDPhD, Hans A. Messner, MD PhD, Jieun Uhm, MD, Naheed Alam, MBBS,MD, David Loach, MD, Laura McGillis, NP, Anna Lambie, NP, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Dennis D. Kim, MD PhD

Blood (2014) 124 (21): 2529.

https://doi.org/10.1182/blood.V124.21.2529.2529

Published: 2014

Journal Articles

Multiple CMV Reactivations Are Associated with Lower Risk of Relapse Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Feras Alfraih, MD, Naheed Alam, MBBS,MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, David Loach, MD, Matthew D. Seftel, MRCP, FRCPC, MPH, Jieun Uhm, MD, Anna Lambie, NP, Hans A. Messner, PhD

Blood (2014) 124 (21): 3955.

https://doi.org/10.1182/blood.V124.21.3955.3955

Published: 2014

Journal Articles

The Benefit of Allogeneic Hematopoietic Cell Transplantation in Older Patients with Acute Myeloid Leukemia Is Restricted to Those in First Complete Remission At the Time of Transplantation.

Fotios V. Michelis, MD, PhD, Hans A. Messner, MD, PhD, Eshetu G Atenafu, MSc, Dennis Dong Hwan Kim, MD, PhD, John Kuruvilla, MD, FRCPC, Jeffrey H. Lipton, MD, PhD, Jieun Uhm, MD, David Loach, MD, Vikas Gupta, MD, FRCP, FRCPath

Blood (2012) 120 (21): 3097.

https://doi.org/10.1182/blood.V120.21.3097.3097

Published: 2012

NARROW

Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Improved Gvhd Free, Relapse Free Survival Using Dual T-Cell Depletion with ATG and Ptcy in Matched Unrelated Donor RIC Allo-HSCT

Dual T-Cell Depletion with a Very Low Dose of ATG and Ptcy Provides an Effective Control of Acute Gvhd in PBSC RIC Allo-HSCT

Outcomes of Therapy Related Acute Lymphoblastic Leukemia in Adults after Allogeneic Stem Cell Transplantation - Twenty-Year Experience from a Tertiary Care Center

Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneichematopoietic Cell Transplantation to Predict Outcomes

Predictors of Outcomes in Adult Patients with Therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Twenty Year Experience from a Tertiary Care Centre

Combination of ATG and Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Peripheral Blood Stem Cell Transplants for High-Risk Hematological Malignancies- a Single Centre Experience

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation

Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience

Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

A Risk Score to Predict CMV Viremia within the First 100 Days after Allogeneic Stem Cell Transplantation Based on Pre-Transplant Parameters

Clinical Characteristics, Risk Factors and Outcomes of CMV Disease after Allogeneic Stem Cell Transplantation

Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Multiple CMV Reactivations Are Associated with Lower Risk of Relapse Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

The Benefit of Allogeneic Hematopoietic Cell Transplantation in Older Patients with Acute Myeloid Leukemia Is Restricted to Those in First Complete Remission At the Time of Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only